Image Source: AsiaOne
MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in PouchitisGlobeNewswireJune 28, 2022GHENT, Belgium, June 28, 2022 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with Pouchitis.
Source: AsiaOne